NDUFA8
ENSG00000119421
Target class
Enzyme
Chromosome
9
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFA8
- Gene name
- NADH:ubiquinone oxidoreductase subunit A8
- Gene symbol
- NDUFA8
- Protein name
- NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 (Complex I-19kD) (CI-19kD) (Complex I-PGIV) (CI-PGIV) (NADH-ubiquinone oxidoreductase 19 kDa subunit)
- PGIV
- MGC793
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 220.34
- Tissue specificity (Gini)
- 0.223
- Tissue specificity (tau)
- 0.572
- KEGG gene identifiers
- hsa:4702
- Protein interaction confidence
- 0.920875
- Protein interaction partners
- 120
- R-HSA-611105
- R-HSA-6799198
- End position
- 122159779
- Start position
- 122144058
- Chromosome
- 9
- Strand
- Reverse
- Mitochondrion inner membrane
- Peripheral membrane protein . Mitochondrion intermembrane space . Mitochondrion .
- End piece
- Mid piece
- Mitochondria
- Principal piece
- PubMed 21310150
- PubMed 23676665
- Tissue specificity (tau)
- 0.571705
- Expression inequality (Gini)
- 0.223497
Expression in transcripts per million
- Heart - Left Ventricle
- 220.34
- Heart - Atrial Appendage
- 208.04
- Testis
- 204.33
- Brain - Frontal Cortex (BA9)
- 172.02
- Colon - Sigmoid
- 162.42
Expression in transcripts per million
- Heart - Left Ventricle220.34
- Heart - Atrial Appendage208.04
- Testis204.33
- Brain - Frontal Cortex (BA9)172.02
- Colon - Sigmoid162.42
- Brain - Nucleus accumbens (basal ganglia)144.26
- Brain - Caudate (basal ganglia)135.59
- Brain - Cortex134.76
- Brain - Anterior cingulate cortex (BA24)131.36
- Muscle - Skeletal129.85
- Esophagus - Muscularis127.78
- Brain - Cerebellar Hemisphere118.89
- Brain - Putamen (basal ganglia)117.97
- Cells - Cultured fibroblasts115.32
- Brain - Hypothalamus111.19
- Esophagus - Gastroesophageal Junction110.59
- Cells - EBV-transformed lymphocytes109.95
- Colon - Transverse103.31
- Brain - Cerebellum102.59
- Pituitary97.85
- Adrenal Gland97.04
- Brain - Substantia nigra96.32
- Brain - Amygdala96.2
- Brain - Hippocampus96.01
- Kidney - Medulla92.54
And 29 more, listed on the interactive page.
- GO:0005739
- GO:0005743
- GO:0005758
- GO:0045271
- GO:0005515
- GO:0008137
- GO:0044877
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor